Translational research in oncology: The need of additional in vitro preclinical testing methods for new drugs

Current Pharmaceutical Design

Volumn 18, Issue 23, 2012, Pages 3416-3420

  Drell IV, Theodore L ^a   Zänker, Kurt S ^b   Entschladen, Frank ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Cell migration; Drug screening; In vitro assays; Invasion; Metastasis; Translational oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; SORAFENIB; SUNITINIB;

ANGIOGENESIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CYTOTOXICITY; DRUG CYTOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCREENING; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84863529078     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801227069     Document Type: Review

References (33)

1. Zaenker KS, Entschladen F. Paving roads for new drugs in oncology. Recent Pat Anticancer Drug Discov 2009; 4: 137-45.
2. European Medicines Agency, Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. London, UK: European Medicines Agency 2011, EMA/CHMP/205/95/rev. 4: p. 5.
3. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-81.
4. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-23.
5. Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models? Eur J Cancer 2009; 45: 2768-81.
6. Boyd MR. The NCI in vitro anticancer drug discovery screen. In: Teicher B Ed, Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa, Humana Press Inc. 1997: 23-42.
7. Miura T, Kubota Y, Sakuramoto T, Hosaka M. A trial of the in vitro sensitivity test of anti-cancer drugs using primary cultured urogenital cancer cells. Urol Res 1987; 15: 187-90.
8. Murata T, Akagi K, Uda M, Kimura H, Nasu R, Tanaka Y. Cell kinetic changes in cultured tumor cells after treatment with radiation and chemotherapy. Int J Oncol 1998; 12: 171-4.
9. Lovborg H, Gullbo J, Larsson R. Screening for apoptosis--classical and emerging techniques. Anticancer Drugs 2005; 16: 593-9.
10. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20.
11. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-56.
12. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
13. Entschladen F, Palm D, Drell TL, Lang K, Zaenker KS. Connecting a tumor to the environment. Curr Pharm Des 2007; 13: 3440-4.
14. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 Suppl 3: 4-10.
15. Strieter RM. Masters of angiogenesis. Nat Med 2005; 11: 925-7.
16. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609.
17. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-70.
18. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat Med 2003; 9: 822-3.
19. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 2009; 90: 195-221.
20. Ucuzian AA, Greisler HP. In vitro models of angiogenesis. World J Surg 2007; 31: 654-63.
21. Entschladen F, Drell TL, Lang K, et al. Analysis methods of human cell migration. Exp Cell Res 2005; 307: 418-26.
22. Gordon IK, Khanna C. Modeling opportunities in comparative oncology for drug development. ILAR J 2010; 51: 214-20.
23. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
24. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112: 231-8.
25. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine- induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61: 2866-9.
26. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118: 2744-9.
27. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70: 7042-52.
28. Powe DG, Voss MJ, Zaenker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-638.
29. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta Blockers and Breast Cancer Mortality: A Population-Based Study. J Clin Oncol 2011; 29: 2635-44.
30. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Betablocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-52.
31. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with betablockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-81.
32. Lemeshow S, Sorensen HT, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population- based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2273-9.
33. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.